Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cenegermin-bkbj in Stage 3 Neurotrophic Keratitis (IMAGO)
NCT06411145Phase 4Withdrawn
- Sponsor
- Dompé
- Start
- Apr 2024
- Primary completion
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 4 trial of cenegermin in neurotrophic keratitis (NK), sponsored by Dompé. Planned start Apr 2024; status: withdrawn.
02
Drugs
cenegermin
03
Conditions
neurotrophic keratitis (NK)
Beyond the preview
Go deeper on NCT06411145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06411145.